Results 31 to 40 of about 247,670 (219)

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke, Jeelall, Yogesh S., Wang, James Q.   +2 more
core   +1 more source

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in ...
A. Younes, L. Sehn, P. Johnson, P. Zinzani, X. Hong, Jun Zhu, C. Patti, D. Belada, O. Samoilova, C. Suh, S. Leppä, S. Rai, M. Turgut, W. Jurczak, Matthew Cheung, R. Gurion, S. Yeh, A. López‐Hernandez, U. Dührsen, C. Thieblemont, C. Chiattone, S. Balasubramanian, J. Carey, Grace Liu, S. Shreeve, Steven Sun, S. Zhuang, J. Vermeulen, L. Staudt, W. Wilson   +29 more
semanticscholar   +1 more source

An unusual and malignant intussusception in a child [PDF]

, 2016
Intussusception is a common cause of bowel obstruction in the pediatric population. Malignant lesions account for up to 30 % of all cases of intussusception in the small intestine. We herein report an interesting case of ileo-colic intussusception caused
Carmelo Romeo, Carmelo Salpietro, Daniela Impollonia, Eloisa Gitto, Gabriella D’Angelo, Giovanni Stroscio, Lucia Marseglia, Marta Manti, Pietro Impellizzeri, Salvatore Arena   +9 more
core   +1 more source

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica, 2014
The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial.
Wyndham H. Wilson, Jacoline E.C. Bromberg, Maryalice Stetler-Stevenson, Seth M. Steinberg, Lourdes Martin-Martin, Carmen Muñiz, Juan Manuel Sancho, Maria Dolores Caballero, Marjan A. Davidis, Rik A. Brooimans, Blanca Sanchez-Gonzalez, Antonio Salar, Eva González-Barca, Jose Maria Ribera, Margaret Shovlin, Armando Filie, Kieron Dunleavy, Thomas Mehrling, Michele Spina, Alberto Orfao   +19 more
doaj   +1 more source

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]

, 2018
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S, Bareja R, Bonvini E, Bruna R, Brusa D, Chiaretti S, Chichili GR, Cignetti A, Circosta P, Deaglio S, Elemento O, Elia AR, Foà R, Giacomo FD, Gottardi D, Guarini AR, Inghirami G., Johnson S, Kyriakides PW, Landra I, Machiorlatti R, Massaia M, Monteleone E, Moore PA, Todaro M   +24 more
core   +1 more source

Dramatic radiotherapy response in a necrotic lymphoma mass: a case report

Journal of Medical Case Reports, 2020
Background Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma and is characterized by an aggressive natural history. It often presents with rapid symptom development and disease progression.
Nicholas McNeil, Peter Gorayski, Danielle Blunt, Daniel Roos   +3 more
doaj   +1 more source

Two Cases of Pelvic Diffuse Large B-Cell Lymphoma

Journal of Investigative Medicine High Impact Case Reports, 2022
Primary diffuse large B-cell lymphoma presenting as an extranodal site in the pelvis is rare and can mimic a gynecological malignancy. Although management for diffuse large B-cell lymphoma is standardized and curative, prognosis depends on timely ...
Rupam Sharma MD, Arash Heidari MD, Everardo Cobos MD, Greti Petersen MD, Amin A. Ramzan MD, Rahul D. Polineni MD   +5 more
doaj   +1 more source

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management

American journal of hematology/oncology, 2021
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment.
Sandra Susanibar-Adaniya, S. Barta
semanticscholar   +1 more source

SnapShot: Diffuse Large B Cell Lymphoma

Cancer Cell, 2014
Diffuse large B cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma (NHL) in adulthood, comprising 30%–40% of all new diagnoses. This aggressive disease can arise de novo or, less frequently, from the clinical evolution of various indolent B cell malignancies. While durable remissions can be achieved in a substantial proportion of cases by
PASQUALUCCI, Laura, Dalla Favera R.
openaire   +3 more sources

JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms. [PDF]

, 2016
JMJD3 (Jumonji domain containing-3), a histone H3 Lys27 (H3K27) demethylase, has been reported to be involved in the antigen-driven differentiation of germinal center B-cells.
Bai, Nan, Han, Jihong, Li, Luyuan, Luo, Yunping, Ren, Guosheng, Shen, Long, Stupack, Dwayne G, Tan, Xiaoyue, Xiang, Rong, Xun, Jing, Zhang, Yan   +10 more
core   +1 more source